An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNβ-1a (Rebif® or Avonex®)

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2010
This article has no abstract
Epistemonikos ID: c81affc52c1a8a3c8f50461b00b3440e6cd47919
First added on: Jan 22, 2025